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Loss of VHR phosphatase causes cell cycle arrest in HeLa carcinoma cells, suggesting that VHR
inhibitionmay be a useful approach to halt the growth of cancer cells. We recently reported that VHR is
upregulated in several cervix cancer cell lines as well as in carcinomas of the uterine cervix. Here we
report the development of multidentate small-molecule inhibitors of VHR that inhibit its enzymatic
activity at nanomolar concentrations and exhibit antiproliferative effects on cervix cancer cells.
Chemical library screening was used to identify hit compounds, which were further prioritized in
profiling and kinetic experiments. SAR analysis was applied in the search for analogs with improved
potency and selectivity, resulting in the discovery of novel inhibitors that are able to interact with both
the phosphate-binding pocket and several distinct hydrophobic regions within VHR’s active site. This
multidentate binding mode was confirmed by X-ray crystallography. The inhibitors decreased the
proliferation of cervix cancer cells, while growth of primary normal keratinocytes was not affected.
These compounds may be a starting point to develop drugs for the treatment of cervical cancer.
Introduction
Protein tyrosine phosphatases (PTPsa) have recently been
implicated in various human diseases, including cancer, and
have been suggested as potential drug targets.1-5VacciniaH1-
related (VHR) phosphatase is a relatively small member of the
subclass of dual-specificity phosphatases6with only 185 amino
acids (Mr 21 kDa) and no apparent targeting domain or
docking site.7 Compared to the phospho-tyrosine (pTyr)-
specific classical PTPs, the crystal structure of VHR revealed
amuch shallower active site, which allowsVHR to act on both
pTyr and phospho-threonine (pThr) in its substrates.8 VHR
has been reported to dephosphorylate extracellular signal-
regulated kinases Erk1/2 and c-Jun N-terminal kinases
Jnk1/2, but not p38.9-11 These mitogen-activated protein
kinases (MAP kinases) mediate major signaling pathways
triggered by extracellular growth factor, stress, or cytokines,12
and regulate cellular processes such as differentiation, proli-
feration, and apoptosis.13,14MAP kinases are activated within
the kinase cascade by phosphorylation at aThr-X-Tyrmotif in
their activation loop, whereas dephosphorylation of this motif
byVHRorotherMAPkinasephosphatases (MKPs) leads to a
conformational change, leaving the kinase domain in an
inactive, closed conformation.15
Unlike many MKPs, VHR expression is not induced in
response to activation of MAP kinases9 but is instead regu-
lated during cell cycle progression.16 Using RNA interference
to knock down endogenous VHR, we have previously shown
that HeLa cervix carcinoma cells that are lacking VHR
arrested at the G1-S and G2-M transitions of the cell
cycle and showed initial signs of senescence. Loss of VHR
increased the expression of the cyclin-dependent kinase
inhibitor p21Cip-waf1, whereas genes of cell cycle regulators,
DNA replication, transcription, and mRNA processing were
downregulated.16 In addition, there have been several reports
showing that prolonged activation of MAP kinase pathways
results in cell cycle arrest and cell senescence.17-21
In our recent study,22 we established a link between VHR
and cervical cancer. We found VHR protein levels upregu-
lated in several cervix cancer cell lines compared to normal
keratinocytes, including human papillomavirus (HPV) posi-
tive cell lines CaSki, HeLa, and SiHa, as well asHPV negative
cell lines HT3 and C33. Moreover, we also found higher
expression levels of VHR in primary cervix cancer biopsies,
including squamous intraepithelial lesions and squamous cell
carcinomas of the uterine cervix.22 This suggested to us that
VHR might be a novel and promising drug target for the
treatment of cervical cancer and that small-molecule inhibi-
tors of VHR should be valuable tools to validate this new
target. Combining high-throughput chemical library screen-
ing and structure-activity relationship (SAR) analysis, we
†X-ray crystallography data was deposited at the PDB database and
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developed compounds that specifically bind to VHR’s active
site in a multidentate fashion. This binding mode, which
makes use of unique features at the protein surface surround-
ing the catalytic pocket, was confirmed by X-ray crystal-
lography. Several of the inhibitors were active in cell-based
assays at low micromolar concentrations and decreased the
proliferation of cervix cancer cell lines significantly.
Results
Chemical Library Screening. A 96-well format in vitro
assay was used to screen a set of 50000 drug-likemolecules of
the DIVERSet library from ChemBridge (ChemBridge,
Inc.). At the used concentration of 0.02 mg/mL, 221 com-
pounds inhibited VHR’s enzymatic activity >60% (average
of n=2) compared to a no-inhibitor control. For further
evaluation, a total of 56 compounds were picked that
inhibitedVHR>90%(average of n=2).Michaelis-Menten
kinetic studies revealed 21 hits that inhibited the enzymewith
Ki values <20 μM (Table 1). Clustering the 21 compounds
by a Tanimoto distance23 of 0.5 resulted in 12 different
clusters and singletons, respectively, indicating a quite
diverse chemical space covered by these molecules. The most
active hit, 2-((Z)-4-oxo-5-((E)-3-phenylallylidene)-2-thio-
xothiazolidin-3-yl)ethane-sulfonic acid 1, inhibited VHR
with a Ki value of 0.81 μM. In a counter screen against the
protein tyrosine phosphatases PTP1B, CD45, HePTP, Shp2,
and YopH, only 1 and 1,4-dimethoxyanthracene-9,10-dione
8were found to be selective for VHR (Figure 1). Of these two
compounds, only 1 showed a clear competitive inhibition
pattern as shown in the Lineweaver-Burk plot in Figure 2A.
In Silico Docking. To study the molecular basis for inhibi-
tion of VHR, we first used in silico docking to dock 1 and 8
into the active site of the VHR crystal structure (PDB code
1J4X, ref 24). Compound 8 failed to dock into the catalytic
pocket, further supporting an inhibition mechanism other
than competitive. Because quinones like 8 are known to
deactivate PTPs by oxidizing the catalytic cysteine residue,25
we discarded 8 from further investigation. As for compound
1, the docking suggested that the sulfonic acid moiety func-
tions as a phosphate mimic and binds into the catalytic
pocket, forming a network of hydrogen bond interactions
with the phosphate binding loop, also called P-loop
(Figure 2B). In support of this, similar compounds lacking
the sulfonic acid moiety did not inhibit VHR. Furthermore,
the docking suggested that the oxo-thioxothiazolidine ring
interacts with the rim of the catalytic pocket, whereas the
diene linker and the phenyl ring make van der Waals inter-
actions with a hydrophobic region, mainly formed by Leu25
and Tyr128 (Figure 2B).
SARAnalysis andAnalogs of LeadCompound 1.By further
analyzing the lipophilic potential of VHR’s active site sur-
face area, we found a total of three distinct hydrophobic
regions surrounding the catalytic pocket (Figure 2B). Com-
pared to active site properties of solved PTP structures and
homologymodels,26 this feature seems to be rather unique to
VHR and, therefore, could be exploited for designing selec-
tive inhibitors. The exposed hydrophobic patches are formed
by Leu25/Tyr128 and Leu16/Tyr23, which make up large
portions of the substrate binding site,24 as well as by Phe68/
Met69, which is part of a loop opposite of the catalytic
pocket (Figure 2B). In an attempt to find analogs of 1 that
could target more than one of these hydrophobic regions, we
kept the oxo-thioxothiazolidinyl-ethanesulfonic acid moiety
as hydrophilic pharmacophore, and subjected it to a sub-
structure search among commercially available compounds.
Nine structures were identified that fulfilled the requirement
of having additional multiple hydrophobic entities to inter-
act with multiple hydrophobic regions in VHR’s active site.
All compounds contained a 1-phenyl-substituted pyrazole
ring, which at its 3-position linked to another, more variable
entity (Table 2). We obtained all nine analogs and subjected
them to direct measurements of VHR inhibition. Indeed,
compounds SA1, SA2, SA3, SA4, and SA5 showed excellent
Table 1. Most Potent VHR Screening Hitsa
a Ki value <20 μM.
*Compounds 11, 13, 19, and 21 are mixtures of
E/Z-isomers.
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IC50 values of 18, 71, 74, 78, and 268 nM, respectively
(Table 2). An aromatic group in position ‘R’, such as the
benzoxy group in compoundsSA1-4, seemed to be verywell
accommodated by the protein, whereas sterically more de-
manding structures, such as the piperidinsulfonyl group in
SA5 or the morpholinosulfonyl group in SA8, were less
favorable. On the other hand, groups such as methoxy in
SA6 or methyl in SA9 seemed to be too small to provide
additional binding energy through van der Waals interac-
tions. Interestingly, compounds SA1-4 only differ in their
substituents at the benzoxy group. Chlorine in the para-
position was most favorable (SA1), whereas substituents in
the ortho-position, such as chlorine (SA2) or fluorine (SA3),
had no effect on inhibitory activity against VHR in vitro.
Testing the five best inhibitors (SA1-5) against a panel of
related PTPs demonstrated that they were at least 1 order of
magnitude less potent for MKP-1, CD45, Cdc25A, PTP1B,
and HePTP (Table 2). Of these phosphatases, MKP-1 and
HePTP share the same physiological substrate with VHR,
namely, the MAP kinase Erk, and MKP-1 is structurally
closely related to VHR.
Cocrystallization and X-ray Structure Analysis. To investi-
gate the nature of the multidentate binding of our inhibitors
experimentally, we attempted to solve the crystal structure of
SA3 bound to VHR. Using the hanging-drop vapor diffu-
sion technique and repeated macroseeding, we obtained
cocrystals of the VHR-SA3 complex. The structure was
solved to 1.9 A˚ resolution bymolecular replacement. Refine-
ment statistics for the complex are presented in Table 3;
R factor and Rfree values were 17.8 and 21.9%, respectively.
After refinement, difference maps (Fo - Fc and 2Fo - Fc)
were used to fit the inhibitor. Clear electron density ofSA3 in
the VHR active site was visible for the oxo-thioxothiazoli-
dinyl-ethanesulfonic acid moiety (Figure 3B). This moiety
occupies the phosphate-binding pocket in VHR, represent-
ing the exact same position and orientation as the phospho-
tyrosine group of a substrate peptide found in the 1J4X.pdb
structure (ref 24, Figure 3A). Thereby, the sulfonic acid
group undergoes multiple hydrogen bond interactions with
backbone nitrogen atoms of the P-loop, and forms a salt
bridge with the guanidinium group of Arg130 (Figure 3B).
Modeling of SA3 into the visible electron density clearly
exhibited the multidentate binding mode of the inhibitor,
including van der Waals interactions of the fluoro-benzoxy
group with Leu16/Tyr23, and the phenyl-pyrazole ring with
Phe68/Met69 in VHR (Figure 3C). Modeling also indicated
that the SA3 hydrophobic entities might have some flexi-
bility in interacting with these amino acid residues, which
could be the reason for the not defined electron density for
these parts of the molecule. In any case, however, modeling
of SA3 into the visible electron density always found the
fluoro-benzoxy and phenyl-pyrazole groups interacting with
multiple hydrophobic patches in a bidentate fashion. Com-
parison of the VHR-SA3 complex with the previously
reported VHR structure (1J4X.pdb) also supported our
binding model. Significant differences in the side chain
positions of Tyr23, Phe68, and Met69 were observed, which
account for specific interactions with SA3 (Figure 3A).
Moreover, parts of the substrate recognition loop immedi-
ately following the N-terminal helix R1 (residues Ser17,
Asp18, Gly19, Ser20, Gly21, and Cys22) were shifted by as
much as 5.7 A˚, compared to 1J4X.pdb, most likely to
accommodate the fluoro-benzoxy group of SA3 and to
avoid unfavorable interactions betweenSA3 andhydrophilic
amino acid residues within this loop region.
Proliferation of Cervix Cancer Cells. We recently found
VHR protein levels upregulated in several cervix cancer cell
lines, as well as in primary cervix cancer biopsies.22 We also
reported that VHR was necessary for proliferation of HeLa
cervix carcinoma cells.16 Therefore, we set out to determine
the effects of our five best VHR inhibitors on cervix cancer
cell lines HeLa and CaSki, as well as on primary normal
keratinocytes. As shown in Figure 4A, proliferation of
primary normal keratinocytes, as measured by cell numbers,
was not affected by any of the inhibitors after 24 h incubation
at a concentration of 20 μM. In contrast, compoundsSA1-5
significantly inhibited the spontaneous proliferation of
Figure 1. Profiling of the 21 most active VHR screening hits at
20 μM against VHR, PTP1B, CD45, HePTP, Shp2, and YopH.
Black arrows indicate compounds 1 and 8, which were found to be
selectively inhibiting VHR.
Figure 2. Characterization of compound 1 (A) Michaelis-Menten
kinetic measurements, Lineweaver-Burk plot for 1 with VHR.
(B) FlexX docking of 1 into the active site of VHR crystal structure
(PDB code 1J4X). The color code of the MOLCAD surface
represents the lipophilic potential (brown: most hydrophobic, blue:
most hydrophilic).
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HeLa cells, compared to a DMSO control, with SA3 being
the most effective one, reducing HeLa cell numbers to less
than 50% (Figure 4A). In a second assay, we measured
proliferation of HeLa and Caski cells by following the
incorporation of tritium (3H) labeled thymidine into the
DNA (Figure 4B,C). A clear antiproliferative effect was
found for all compounds, thoughmore pronounced in CaSki
compared toHeLa cells. InHeLa cells, SA3 revealed the best
antiproliferative effect, reducing cell growth by as much as
58% compared to DMSO alone. For all other compounds,
the inhibition did not exceed 30% (Figure 4B). InCaSki cells,
however, all inhibitors reduced the spontaneous prolifera-
tion by more then 50%, with SA3 being most effective,
decreasing the proliferation by as much as 74%
(Figure 4C). To exclude that this decrease in cell prolifera-
tion was due to apoptosis, we incubated HeLa and Caski
cells with 20 μM SA3 or SA2 for 24 h, stained cells with
AnnexinV and propidium iodide (PI), and used flow cyto-
metry to determine the percentage of apoptotic cells. As
Figure 4D clearly shows, there was no difference between the
percentages of AnnexinV/PI negative cells in samples treated
with the inhibitors or treated with the vehicle, clearly indi-
cating that the observed antiproliferative effect of the com-
pounds was not due to apoptosis.
Discussion and Conclusions
In this study we used high-throughput chemical library
screening in a first step to generate hits for VHR, which were
further prioritized throughMichaelis-Menten kinetic studies
and counter screens against a number of structurally related
phosphatases. The resulting lead compound 1 competitively
inhibited VHR with a Ki value of 0.81 μM and exhibited a
promising degree of selectivity for VHR among other PTPs.
In silico docking of 1 into the active site of VHR and SAR
analysis suggested a binding mode, in which the sulfonic acid
moiety of 1 binds through a network of hydrogen bond
interactions into the phosphate binding pocket, whereas the
thiazolidine heterocycle interacts with the rim of the pocket
and the phenyl-allyl moietymakes van derWaals interactions
with side chains of hydrophobic amino acids that flank the
active site.
Table 2. In Vitro Efficacy and Selectivity of 1-Phenylpyrazole Derivatives
Table 3. Summary of Crystallographic Data and Refinement Statistics
for the VHR-SA3 Complexa
Crystallographic Data
space group P21
unit cell (A˚) a = 50.406, b= 59.186, c= 60.656
a= 90.00, b= 98.36, g= 90.00
molecules/asymmetric unit two monomers
resolution range (A˚) 50-1.9
data completeness (%) 99.1 (99.7)




R factor (%) 17.8 (18.4)
Rfree (%) 21.9 (23.6)
avg B factor (A˚2) 15.5
No. protein atoms 2784
No. inhibitor atoms 28
No. water atoms 227
rmsd bond length (A˚) 0.016
rmsd bond angle 1.724
aValues for the highest resolution shell (1.95-1.90 A˚) are given in
parentheses.
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The sulfonic acid headgroup is an ideal chemical structure
to mimic a phosphate group without undergoing any hydro-
lysis reaction. Phosphorus and sulfur atoms have similar
atomic and van der Waals radii, and are coordinated by four
(phosphate) or three (sulfonate) oxygen atoms, respectively.
However, under physiological pH conditions, a phosphate
group carries two negative charges, whereas the sulfonate has
onlyone,making it easier for compounds carrying the latter to
penetrate cell membranes. We therefore decided to keep the
oxo-thioxothiazolidinyl-ethanesulfonic acid moiety of 1 as
pharmacophore and applied a structure-based approach to
optimize 1 in terms of both potency and selectivity.
Examination of the surface area that surrounds the active
site inVHR revealed several distinct hydrophobic regions that
were exploited in the design of more potent and selective
inhibitors.A search for compounds thatwould still bind to the
catalytic pocket, and additionally could interact with not just
one but multiple hydrophobic areas in a multidentate fashion
resulted in five molecules with significant lower IC50 values
than lead structure 1. These compounds contain a thioxothia-
zolidinyl-ethanesulfonic acid moiety, representing the defined
pharmacophore in 1. In addition, a pyrazole ring functions as
a linker from which two hydrophobic entities branch off:
a phenyl ring in 1-position and a more variable group at
3-position. Cocrystallization of VHR with one of these com-
pounds, SA3, yielded a crystal structure in which clear
electron density of SA3 was observed for the thioxothiazoli-
dinyl-ethanesulfonic acidmoiety.As predicted by the docking
studies, the sulfonic acid group was found to bind tightly into
the catalytic pocket, mimicking the phosphate group of the
natural substrate. No clear electron density was observed for
the two hydrophobic entities of SA3, which is most likely due
to some degree of flexibility in the interactions between these
parts of the molecule and the hydrophobic amino acid
residues of the protein. Nonetheless, modeling of SA3 into
the visible electron density leaves no doubt about the biden-
tate fashion thatSA3 employs to bind to distinct hydrophobic
patches at the surface that flanks the catalytic pocket in VHR.
Besides highly improved potency against VHR with IC50
values as low as 18 nM, these multidentate inhibitors were
at least 1 order of magnitude less potent for any other PTP
tested, including HePTP and MKP-1, which share the same
physiological substratewithVHR.This result provides a good
example for a general applicable concept, in which targeting
unique surface features outside of the catalytic pocket can
generate selective small-molecule inhibitors for individual
members of the PTP family.
Wealsopresent several lines of evidence strongly suggesting
that our VHR inhibitors are able to pass cell membrane
barriers and target VHR in cultured cells. In particular, we
tested our compounds in cervical cancer cells, which were
shown earlier to express higher levels of endogenous VHR
compared to noncancerous cells of the cervix. Indeed, incuba-
tion of the cancer cell linesHeLaandCaSkiwith the inhibitors
at 20 μM induced a very significant inhibition of cell proli-
feration after an incubation period as short as 24 h. This
inhibition of cell growthwas not due to cell death and is also in
accordance with our previous work, demonstrating that loss
of VHRusingRNAi induces a dramatic decrease ofHeLa cell
numbers and proliferation. It is interesting to note that SA3
was more effective in inhibiting proliferation than SA1,
although its IC50 value is four times higher in vitro. SA3 also
exhibited greater antiproliferative effects than SA2 and SA4,
both of which share similar IC50 values with SA3 in vitro.
These results suggest a beneficial role for the fluorine sub-
stituent (which is only present in SA3), maybe by facilitating
Figure 3. X-ray structural analysis of the VHR-SA3 complex. (A) Stereo ribbon diagram of the overall cocrystal structure of the VHR-SA3
complex (green), alignedwithX-ray coordinates of aVHR-substrate peptide complex (1J4X.pdb,VHRgray, peptide light-blue). Tyr23, Phe68,
and Met69 (green and gray, respectively), as well as the oxo-thioxothiazolidinyl-ethanesulfonic acid moiety of SA3 (magenta) and pTyr from
the peptide (light-blue) are highlighted in stick representation. (B) Close-up of SA3 bound to VHR’s active site with visible electron density.
Yellow dashed lines indicate hydrogen bond interactions of the sulfonic acidmoiety with amino acid residues of the P-loop at the bottom of the
catalytic pocket. (C) Modeling of SA3 into visible electron density. White arrows indicate multiple van der Waals interactions with
hydrophobic regions at the surface surrounding VHR’s catalytic pocket.
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better membrane permeability. The latter could be a limiting
factor for these compounds, considering the substantially
higher concentration that is needed to see clear effects in cells
vs inhibition of recombinant protein. Nonetheless, the fact
that our inhibitors are not toxic to cells with low levels of
endogenous VHR, such as primary normal keratinocytes,
these compounds may well be a starting point to develop
drugs for the treatment of cervical cancer and perhaps other
cancers. Indeed, our results provide first evidence that phar-
macological inhibition of VHR could be beneficial in treating
such diseases.However, additional studieswill be necessary to
get better insights into the role of VHR phosphatase in cell
cycle regulation and cancer and to test the activity of these
compounds in vivo using mouse models.
Materials and Methods
Reagents. p-Nitrophenyl phosphate (pNPP) was purchased
from Sigma-Aldrich (St. Louis, MO). BIOMOL GREEN re-
agent was from BIOMOL Research Laboratories, Inc.
(Plymouth Meeting, PA). 6,8-Difluoro-4-methylumbelliferyl
phosphate (DiFMUP) was from Invitrogen Inc. (Carlsbad,
CA). The 56 hit compounds were purchased from ChemBridge
Inc., the sulfonic acid compounds were from Sigma, and all
compounds had a purity of >95%. All other chemicals
and reagents were of the highest grade available commercially.
The anti-VHR monoclonal antibody was from Transduction
Laboratories (Los Angeles, CA). Anti-Erk and anti-p38 were
from Cell Signaling Technology Inc. (Beverly, MA); anti-
phospho-Erk and antiphospho-p38 were from Promega
(Madison, WI).
Recombinant PTPs. Recombinant VHR, HePTP, and YopH
were expressed in E. coli and purified as described previously.20
Recombinant CD45, PTP1B, MKP-1, and Cdc25A were pur-
chased from BIOMOL Research Laboratories, Inc. (Plymouth
Meeting, PA). Shp2 was generously provided byDr. Gen-Sheng
Feng.
Chemical Library Screening. A set of 50000 drug-like mole-
cules from the DIVERSet library (ChemBridge, Inc.) was
screened in a 96-well format in vitro phosphatase assay. Com-
pounds had a working concentration of 0.15 mg/mL in 10%
DMSO. Each reaction contained 180 nM VHR, 4 mM pNPP,
and 0.02 mg/mL compound in 0.1 M Bis-Tris pH 6.0 reaction
buffer with 1 mM dithiothreitol (DTT) present. The final
volume amounted to 70 μL and contained 1.4% DMSO. The
reaction was initiated by addition of pNPP after a preincubation
of the enzyme with compounds for 10min at room temperature.
After 15 min, the reaction was quenched by addition of 140 μL
BIOMOL GREEN reagent, and the pNPP hydrolysis was
determined by measuring the absorbance of the complexed free
phosphate at 620 nm. The nonenzymatic hydrolysis of the
substrate was corrected by measuring the negative control
without addition of enzyme. Other controls included a positive
control (no inhibitor added), a background control (no sub-
strate added), and a control with 200 μM of the general PTP
inhibitor sodium orthovanadate. To quantitate the inhibitory
efficacy of the library compounds, we determined the ratio of
inhibition in comparison to the positive control. Every com-
pound with>60% inhibition was cherry-picked and rescreened
to confirm it as a hit.
IC50 Measurements. The PTP-catalyzed hydrolysis of 6,8-
difluoro-4-methylumbelliferyl phosphate (DiFMUP) in the
presence of compound was assayed at 30 C in a 60 μL 96-well
format reaction system in 150 mM Bis-Tris, pH 6.0, assay
buffer having an ionic strength of 150 mM (adjusted with
NaCl) and containing 1 mMDTT and 5%DMSO. At various
concentrations of the compound, the initial rate at fixed
DiFMUP concentration (equal to the corresponding Km value
for each PTP) was determined using a FLx800 microplate
reader (Bio-Tek Instruments, Inc.), an excitation wavelength
of 360 nm, and measuring the emission of the fluore-
scent reaction product 6,8-difluoro-7-hydroxy-4-methylcou-
marin (DiFMU) at 460 nm. The nonenzymatic hydrolysis
of the substrate was corrected by measuring the control with-
out addition of enzyme. The IC50 value was determined by
plotting the relative activity versus inhibitor concentration and
fitting to eq 1 using the software GraphPad Prism (GraphPad
Figure 4. Effects of VHR inhibitors on proliferation and survival
of cervix cancer cells. (A) Cell numbers of HeLa cervix carcinoma
cells and normal keratinocytes (NK) after 24 h of treatment with
20 μM inhibitors, given as percentage of the DMSO control. (B,C)
[3H]-Thymidine incorporation assay with 20 μM inhibitors or
vehicle (DMSO) in HeLa (B) or Caski (C) cervix cancer carcinoma
cells. (D) Survival/death of HeLa and CasKi cells in presence of
20 μM inhibitors or DMSO after 24 h, evaluated by AnnexinV-
FITC/PI flow cytometry assay (FACSVantage, BD). Percentage of
live cells (Annexin V negative and PI negative cells on flow
cytometry dot plots) is given. All data are reported as mean ( SD
from three independent experiments.
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Software, Inc.).
Vi=V0 ¼ IC50=ðIC50þ½I Þ (1Þ
In this case, Vi is the reaction velocity when the inhibitor
concentration is [I],V0 is the reaction velocity with no inhibitor,
and IC50=Ki þ Ki[S]/Km.
Ki Determination. The same format and buffer system as for
IC50 measurements was used, where the enzyme was preincu-
bated with various fixed concentrations of inhibitors for 10min.
The reaction was initiated by addition of various concentrations
of pNPP (ranging from 0.2 to 10 Km) to the reaction mixture.
The initial rate was determined using an ELx808 microplate
reader (Bio-Tek Instruments, Inc.), reading the absorbance of
the product p-nitrophenol at 404 nm. The nonenzymatic hydro-
lysis of the substrate was corrected by measuring the control
without addition of enzyme. The inhibition constant and
inhibition pattern was evaluated by fitting the data to the
Michaelis-Menten equations for either competitive, uncompe-
titive, or mixed inhibition as described before,27 using nonlinear
regression and the program GraphPad Prism (GraphPad Soft-
ware, Inc.). For a comparison of the fitting results, the second-
order Akaike’s Information Criterion (AICc) was calculated as
previously described.27
MolecularModeling and In Silico Docking.Molecular model-
ing studies were conducted on a Linux workstation with the
software package SYBYL version 7.1 (TRIPOS). Energy-mini-
mized molecular models of the compounds were generated by
the SYBYL/CONCORD routine. Flexible ligand docking cal-
culations were performed with FlexX as implemented in Sybyl.
For each compound, 30 solutions were generated and ranked by
their FlexX score and CSCORE. The coordinates of the three-
dimensional structure of the catalytic domain of VHR (PDB
code 1J4X, ref 24) were used in the docking studies, and the
binding pocket was defined as an 8 A˚ radius within the catalytic
cysteine 124. Molecular surfaces were generated with MOL-
CAD as implemented in Sybyl. The chemical clustering uses
Tanimoto distance as calculated with the program ICM Pro
(Molsoft, Inc.), which, by default, uses binary fingerprints of the
molecular properties.
Cocrystallization of VHR with Compound SA3. VHR (amino
acids 3-185) was subcloned into pGEX vector (GE Healthcare
Life Sciences), overexpressed inE. coliBL21 (DE3), andpurified
as GST-fusion protein by affinity chromatography (glutathione
sepharose 4B). After cleavage of GST by thrombin digestion
and purification by gel filtration, the purified enzymewas stored
at -20 C in 50 mM Tris pH 7.4, 1 mM EDTA, and 10 mM
DTT. The recombinant protein was confirmed by mass spec-
troscopy, finding amolecularweight of 20259.3Da compared to
the predicted molecular weight of 20260.0 Da. For crystalliza-
tion, the stocked VHR was mixed with inhibitor SA3 to a final
concentration of 0.37 mMVHR and 1.0 mM SA3, respectively.
When the hanging-drop vapor diffusion technique was used,
VHR-SA3 was crystallized in the hanging drop of 2 mL of
protein solutionmixed with 2mL of reservoir solution (100mM
Tris pH 7.4, 15% polyethylene glycol 8000, 60 mM NaF) at
24 C. The crystals for data collectionwere obtained by repeated
macroseeding. The crystal was flash frozen in a stream of
nitrogen gas to 140 K. The diffraction data was collected using
a R-AXIS IV detector with a wavelength of 1.5418 A˚ and
oscillation of 1. The data were processed using the HKL2000
program package.28 The structure of the VHR-SA3 complex
was solved with molecular replacement using a reported VHR
crystal structure (PDB code 1VHR, ref 8) as search model and
the program Molrep as implemented in CCP4.29 An iterative
process of refinement in CCP4 and model building using the
programCoot30 was used to construct themodel of the complex.
The SA3 ligand dictionary file used in CCP4 and Coot was
generated with PRODRG.31 After refinement, difference maps
(Fo - Fc and 2Fo - Fc) were used to fit the inhibitor. Clear
electron density was visible for only the partial inhibitor in the
VHR active site. Refinement statistics for the complex are
presented in Table 2. For the final structure, R factor and Rfree
values were 17.8 and 21.9%, respectively. Graphic images
presented in the figures were prepared with PyMol (DeLano
Scientific, Palo Alto, CA).
Cell Lines and Primary Keratinocytes. HeLa and CaSki cells
were grown in DMEM medium (Dulbecco’s modified Eagle’s
medium; ICN; lowLaboratories) complemented with 10% (v/v)
heat inactivated fetal calf serum (FCS), 30 units/mL of peni-
cillin, 30 μg/mL of streptomycin, 1 mM sodium pyruvate, 1%
(v/v) nonessential amino acids (100), and 2 mM of L-gluta-
mine. Normal keratinocytes were prepared from hysterectomies
as described previously.22 Briefly, fragments were plunged in a
solution containing gentamycin, fungizon, and antimycoplasm.
These fragments were cut in smaller pieces and then incubated in
trypsin-EDTA (Invitrogen) at 37 C under agitation for 1-2 h.
The epithelium was scraped and cells were recovered in FCS.
After centrifugation, the cells were resuspended in K-SFM
medium (serum-free media; Invitrogen) complemented with
EGF (0.1 ng/mL), pituitary hormone (20-30 μg/mL), and
gentamycin (5 μg/mL).
Cell Proliferation, Survival, and Apoptosis Assays. To evalu-
ate the effect of the inhibitors on viability and apoptosis ofHeLa
andCaSki cells and primary normal keratinocytes, 105 cells were
incubated for 24 h with 20 μMof the different inhibitors or with
the vehicle (DMSO). Cells were then trypsinized and counted on
a thomacytometer plate using trypan blue. Both death (blues
cells) and live cells were counted. Half of the collected cells
were stainedwithAnnexinV and propidium iodide and analyzed
by flow cytometry to evaluate the percentage of apoptotic and
death cells. Proliferation assays were performed by incubation
of 5  104 HeLa or CaSki cells in 200 mL of DMEM complete
medium in flat-bottomed 96-wellmicrotiter plates. Proliferation
was analyzed after incubating cells for 24 h with 20 μM
inhibitors or DMSO, adding [3H]thymidine (0.4 mCi) for
the last 4 h, before collecting cells with a cell harvester
(Skatron, Sterling, VA) onto glass fiber filters, and counting
radioactivity using a scintillation analyzer (Tri-Carb, Packard,
Meriden, CT).
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